title: [Effect of intravenous propafenone on maintenance of atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
abstract: The aim of this study was evaluation of intravenous propafenone hydrochloride effects on maintenance of atrial signal-averaged ECG (ASAECG) during time-domain and frequency-domain analyses in patients paroxysmal atrial fibrillation (PAF) accompanying ischemic heart disease (IHD). The study population of 20 patients included 12 women and 8 men (mean age 58.8 +/- 8.9). For ASAECG were calculated time-domain parameters: the root mean square voltage of the signals in the last 10, 20, 30 ms of the filtered P-wave (RMS 10, 20, 30) and duration of filtered P-wave (PWD). During frequency-domain analysis of the terminal part of P-wave the following parameters were calculated in the range from 40 Hz to 400 Hz: energy spectrum > -60 dB (A, YA) and decibel drop at 40 Hz (Dd, YDd) in logarithmic scale and area ratio 20-50/0-20 Hz (Ar, YAr), peak (P1-7, YP1-7), magnitude ratio (MR1-7, YMP1-7) in linear scale for a vector magnitude and Frank lead Y. Time-domain analysis of ASAECG did not show any significant changes--RMS10 increased from 5.2 +/- 2.5 microV to 5.9 +/- 2.6 microV, RMS20 from 6.9 +/- 3.4 microV to 7.3 +/- 2.5 microV and RMS30 from 8.4 +/- 3.1 microV to 8.5 +/- 2.2 microV after propafenone. Duration of filtered P-wave (PWD) increased from 125.1 +/- 21.9 ms to 128.4 +/- 22.7 ms (p > 0.05). During frequency-domain analysis both in linear and logarithmic scales no any significant differences after administration of propafenone were noted. The obtained results have indicated that intravenous propafenone hydrochloride did not change significantly time-domain and frequency-domain parameters of ASAECG in patients with PAF during IHD.
authors.affiliation: Kliniki Chorób Wewnetrznych Wojskowego Szpitala Klinicznego we Wrocławiu.
authors.forename: W
authors.initials: W
authors.lastname: Banasiak
authors.forename: J
authors.initials: J
authors.lastname: Zebrowski
authors.forename: K
authors.initials: K
authors.lastname: Wiech
authors.forename: A
authors.initials: A
authors.lastname: Telichowski
authors.forename: K
authors.initials: K
authors.lastname: Kokot
authors.forename: R
authors.initials: R
authors.lastname: Zapałowicz
authors.forename: M
authors.initials: M
authors.lastname: Pieróg
authors.forename: W
authors.initials: W
authors.lastname: Lacheta
authors.forename: C
authors.initials: C
authors.lastname: Telichowski
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000627:therapeutic use*; D013614:Tachycardia, Paroxysmal / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D011405:Propafenone